Sitagliptin improved glycemic control and β-cell function in type 2 diabetes

March 2007
ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p39
Academic Journal
The article presents a study which states that sitagliptin improved glycemic control and ß-cell function in type 2 diabetes. In the study, 741 patients from 18 to 75 years of age who had type 2 diabetes mellitus with inadequate glycemic control on diet and exercise, had mean hemoglobin (Hb) A[sub 1c] 8.0% and had adequate compliance during the placebo run-in period.


Related Articles

  • Rosiglitazone reduced type 2 diabetes but increased heart failure in patients with impaired glycemic control. Gandhi, Gunjan Y.; Swiglo, Brian A. // ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p8 

    The article cites a study regarding the effectiveness of rosiglitazone for the treatment of type 2 diabetes in patients with impaired glucose tolerance. The study was conducted by researcher H.C. Gerstein and colleagues, and published in the journal "The Lancet." There were few patients with...

  • Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycaemic control in patient with type 2 diabetes mellitus. Shimpi, R. D.; Patil, P. H.; Kuchake, V. G.; Ingle, P. V.; Surana, S. J.; Dighore, P. N. // International Journal of PharmTech Research;Jan2009, Vol. 1 Issue 1, p50 

    The aim of the present study is to compare the effect of metformin in combination with Glimepiride and Glibenclamide In patient with type 2 Diabetes Mellitus. Subjects and method: This is an open-label, randomized study carried out to study the effect of metformin when it is given in combination...

  • Group training most effective for diabetes.  // GP: General Practitioner;7/1/2005, p12 

    This article informs that British researchers have found group-based training to be the most effective way to deliver education to patients with type-2 diabetes. The researchers evaluated 11 studies that included 1,532 patients with type-2 diabetes. There were equal numbers of men and women, and...

  • Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis. Merlotti, Claudia; Morabito, Alberto; Ceriani, Valerio; Pontiroli, Antonio // Acta Diabetologica;Oct2014, Vol. 51 Issue 5, p853 

    Different intervention strategies can prevent new cases of type 2 diabetes (T2DM) in obese subjects. The present systematic review and meta-analysis evaluates the effectiveness of different strategies in prevention of type 2 diabetes in obese subjects. Studies were grouped into five different...

  • Review: Lifestyle or pharmacologic interventions prevent or delay type 2 diabetes in impaired glucose tolerance: COMMENTARY. Bhagra, Sumit; Smith, Steven A. // ACP Journal Club;Jul/Aug2007, Vol. 147 Issue 1, p1 

    The authors reflect on a study, conducted by C.L. Gillies and colleagues, which focuses on the effectiveness of pharmacologic and lifestyle interventions in preventing type 2 diabetes mellitus (DM) in persons with impaired glucose tolerance. They view that sustained effects from preventive...

  • Salicylate (Salsalate) in Patients With Type 2 Diabetes. Goldfine, Allison B.; Fonseca, Vivian; Jablonski, Kathleen A.; Ida Chen, Yii-Der; Tipton, Laura; Staten, Myrlene A.; Shoelson, Steven E. // Annals of Internal Medicine;7/2/2013, Vol. 159 Issue 1, p1 

    Background: Short-duration studies show that salsalate improves glycemia in type 2 diabetes mellitus (T2DM). Objective: To assess 1-year efficacy and safety of salsalate in T2DM. Design: Placebo-controlled, parallel trial; computerized randomization and centralized allocation, with patients,...

  • Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin. Wilding, John P. H.; Woo, Vincent; Soler, Norman G.; Pahor, Andrea; Sugg, Jennifer; Rohwedder, Katja; Parikh, Shamik // Annals of Internal Medicine;3/20/2012, Vol. 156 Issue 6, p405 

    Background: Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the associated weight gain in patients with inadequate control despite high doses of insulin. Objective: To evaluate the efficacy and safety...

  • Use of Twice-Daily Exenatide in Basal Insulin--Treated Patients With Type 2 Diabetes. Buse, John B.; Bergenstal, Richard M.; Glass, Leonard C.; Heilmann, Cory R.; Lewis, Michelle S.; Kwan, Anita Y. M.; Hoogwerf, Byron J.; Rosenstock, Julio // Annals of Internal Medicine;1/18/2011, Vol. 154 Issue 2, p103 

    Background: Insulin replacement in diabetes often requires prandial intervention to reach hemoglobin A1c (HbA1c) targets. Objective: To test whether twice-daily exenatide injections reduce HbA1c levels more than placebo in people receiving insulin glargine. Design: Parallel, randomized,...

  • Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus. Gami, Apoor S.; Smith, Steven A. // Evidence Based Medicine;Apr2005, Vol. 10 Issue 2, p43 

    The article cites a research study, which reported that atorvastatin reduced malor cardiovascular disease events in type 2 diabetes mellitus. The researchers concluded that in patients with type 2 diabetes mellitus, atorvastatin reduced major cardiovascular disease events. It reported that The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics